Stock Groups

China gives conditional approval for Pfizer’s COVID drug Paxlovid -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – Coronavirus disease (COVID-19), treatment pill Paxlovid, is shown in a box at Misericordia Hospital in Grosseto in Italy, February 8th, 2022. REUTERS/Jennifer Lorenzini

BEIJING (Reuters), – China’s regulator for medical products stated on Saturday that they have given conditional approval. Pfizer Paxlovid, a COVID-19 medication Paxlovid for adults suffering from mild or moderate diseases and at high risk of developing into severe conditions (NYSE:).

National Medical Products Administration stated that further studies on the drug were required before they could be presented to the agency.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]